Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Comments

Loading...

Antibe Therapeutics

ATBPFOTCEM

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$0.2156

At close: Mar 5, 8:00 AM EDT

$0.3780

0.1675.32%

After Hours: Mar 5, 8:00 AM EDT

Antibe Therapeutics (ATBPF) Forecast

News

Earnings Antibe Therapeutics (ATBPF) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest news for Antibe Therapeutics (OTC:ATBPF) Stock

Antibe Therapeutics Stock (OTC: ATBPF)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Monday, September 12, 2022

ATE.TO: Plans on Track for Acute Pain Program for Otenaproxesul…
Zacks Small Cap Research

Friday, July 08, 2022

ATE.TO: Phase 2 Post-Operative Pain Program to Initiate in Calendar 4Q22…
Zacks Small Cap Research

Wednesday, February 16, 2022

ATE.TO: First Human PK/PD Studies Underway in Otenaproxesul's Post-Operative Pain Program…
Zacks Small Cap Research

Wednesday, December 01, 2021

ATE.TO: Development Plan in Place for Otenaproxesul in Acute Pain…
Zacks Small Cap Research

Monday, October 18, 2021

ATE.TO: Pivoting to Acute Pain Relief for Otenaproxesul…
Zacks Small Cap Research

Friday, August 27, 2021

ATE.TO: Awaiting Update on Otenaproxesul Following AME Study Pause
Zacks Small Cap Research

Wednesday, August 04, 2021

ATE.TO: Unexpected Liver Enzyme Elevations Leads to Pause in AME Trial…
Zacks Small Cap Research

Thursday, July 01, 2021

ATE.TO: Phase 3 Enabling Activities Ongoing; Phase 3 Adaptive Trial to Initiate 1Q22…
Zacks Small Cap Research

Tuesday, March 24, 2020

Stocks That Hit 52-Week Highs On Tuesday
Benzinga Insights

Monday, February 10, 2020

Stocks That Hit 52-Week Highs On Monday
Lisa Levin

Friday, January 31, 2020

Stocks That Hit 52-Week Highs On Friday
Lisa Levin

Wednesday, October 30, 2019

Stocks That Hit 52-Week Highs On Wednesday
Lisa Levin

Tuesday, October 29, 2019

Stocks That Hit 52-Week Highs On Tuesday
Lisa Levin

Popular Channels

PreMarket Playbook
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved